Financings in Brief: T Cell Sciences
This article was originally published in The Gray Sheet
Executive Summary
T Cell Sciences: Raises $6.4 mil. in private placement of 2.55 mil. shares of common stock. "Several institutional investors and private investors" participated in the placement, the firm says. T Cell's diagnostics subsidiary received 510(k) clearance from FDA earlier this year for its TRAx CD4 immunoassay test kit ("The Gray Sheet" May 22, p. 18). However, most of the proceeds from the offering will be put toward advancing the company's complement inhibitor program, T Cell says...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.